Article Sidebar
Published:
Oct 13, 2014Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
A Report of Six Clinical Cases of Lowered Blood Cholesterol Profile Associated with Supplementation with Polypeptide K (Diabegard<sup>®</sup>), a Polypeptide Isolated from the Seeds of <i>Momordica charantia</i> Linn
Abstract
Purpose: To assess six patients with Diabegard® supplementation with reference to cholesterol profiles.
Methods: We report the clinical courses of six individuals taking Diabegard® supplementation at 60 and 120 mg/day for 8 weeks.
Results: Patients had a maximum of 52.13 % reduction in low-density lipoprotein (LDL) cholesterol, 47.67 % reduction in triglycerides and 35.78 % reduction in total cholesterol (TC) within 8 weeks of Diabegard® supplementation. Interestingly, high-density lipoprotein (HDL) cholesterol increased by approximately 23.29 %. Patients also had reduced readings for C-reactive protein (CRP) and homocysteine (with maximum reduction of 81.58 % and 57.41 % respectively). In some patients, these parameters were elevated prior to supplementation.
Conclusion: These results suggest that supplementation of Diabegard® will improve patients’ cholesterol profile by reduction of LDL and TC. Patients also expressed lower CRP and homocysteine indicating reduced inflammation and reduction of cardiovascular diseases (CVD) risk. However, patients taking this supplementation are advised to seek medical consultation in monitoring their cholesterol and other biochemical profile levels.
Keywords: Hypocholesterolemia, Diabegard®, Momordica charantia, C-reactive protein, Inflammation, Cardiovascular disease
